ATE188036T1 - Glykoalkaloide - Google Patents
GlykoalkaloideInfo
- Publication number
- ATE188036T1 ATE188036T1 AT91901984T AT91901984T ATE188036T1 AT E188036 T1 ATE188036 T1 AT E188036T1 AT 91901984 T AT91901984 T AT 91901984T AT 91901984 T AT91901984 T AT 91901984T AT E188036 T1 ATE188036 T1 AT E188036T1
- Authority
- AT
- Austria
- Prior art keywords
- cells
- abnormal
- cellular
- removal
- normal
- Prior art date
Links
- 229930008677 glyco alkaloid Natural products 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 6
- 230000002159 abnormal effect Effects 0.000 abstract 4
- 230000001413 cellular effect Effects 0.000 abstract 2
- 244000052769 pathogen Species 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000004520 agglutination Effects 0.000 abstract 1
- 229930013930 alkaloid Natural products 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 abstract 1
- 230000004900 autophagic degradation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000000947 motile cell Anatomy 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 230000035935 pregnancy Effects 0.000 abstract 1
- 238000005211 surface analysis Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0042—Nitrogen only
- C07J71/0052—Nitrogen only at position 16(17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0057—Nitrogen and oxygen
- C07J71/0068—Nitrogen and oxygen at position 16(17)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/14—Topical contraceptives and spermacides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPJ824390 | 1990-01-18 | ||
PCT/AU1991/000020 WO1991010743A1 (en) | 1990-01-18 | 1991-01-18 | Glycoalkaloids |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE188036T1 true ATE188036T1 (de) | 2000-01-15 |
Family
ID=3774458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT91901984T ATE188036T1 (de) | 1990-01-18 | 1991-01-18 | Glykoalkaloide |
Country Status (11)
Country | Link |
---|---|
US (1) | US5958770A (de) |
EP (1) | EP0515386B1 (de) |
JP (1) | JP3168542B2 (de) |
KR (1) | KR100213805B1 (de) |
AT (1) | ATE188036T1 (de) |
AU (1) | AU654474B2 (de) |
BR (1) | BR9105952A (de) |
CA (1) | CA2073855C (de) |
DE (1) | DE69131861T2 (de) |
SG (1) | SG50585A1 (de) |
WO (1) | WO1991010743A1 (de) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994004556A1 (en) * | 1992-08-21 | 1994-03-03 | New York University | Aminofurostenes, compositions, and methods of use |
GB9618119D0 (en) * | 1996-08-30 | 1996-10-09 | Univ Southampton | Adjuvants for use in vaccines |
GB9923076D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
JP3768100B2 (ja) * | 1998-03-26 | 2006-04-19 | ファイトファーム・ピーエルシー | アルツハイマー病を治療するためのステロイドサポゲニンとその誘導体 |
US7291626B1 (en) * | 1998-04-09 | 2007-11-06 | John Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
US6867216B1 (en) | 1998-04-09 | 2005-03-15 | Johns Hopkins University School Of Medicine | Inhibitors of hedgehog signal pathways, compositions and uses related thereto |
AU768130B2 (en) * | 1998-04-09 | 2003-12-04 | Johns Hopkins University School Of Medicine, The | Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways |
US6344050B1 (en) | 1998-12-21 | 2002-02-05 | Light Sciences Corporation | Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue |
AU2005201269C1 (en) * | 1999-01-13 | 2008-09-04 | Curis, Inc. | Regulators of the PCT or smoothened pathway, compositions and uses related thereto |
US6291516B1 (en) | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
GB9923078D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
AUPP968699A0 (en) * | 1999-04-09 | 1999-05-06 | Cura Nominees Pty Ltd | Therapeutic compositions and method for their preparation |
TW471968B (en) * | 1999-08-25 | 2002-01-11 | Committee On Chinese Medicine | Solamargine pharmaceutical composition for killing cancer cells |
GB9923077D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
WO2001027135A2 (en) | 1999-10-13 | 2001-04-19 | Johns Hopkins University School Of Medicine | Regulators of the hedgehog pathway, compositions and uses related thereto |
GB0000228D0 (en) * | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
EE200200613A (et) | 2000-04-28 | 2004-04-15 | Inflazyme Pharmaceuticals Limited | 3-lämmastik-6,7-dihapniksteroidid ja nende kasutamine |
GB0107822D0 (en) * | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
EP1421100B1 (de) * | 2001-08-21 | 2008-07-09 | GlycoMed Sciences Limited | Chemische synthese von solamargin |
ATE312118T1 (de) | 2001-09-28 | 2005-12-15 | Glycomed Sciences Ltd | Lösungsmittelextraktionsverfahren |
WO2003030915A1 (en) * | 2001-10-09 | 2003-04-17 | Glycomed Sciences Limited | Use of solamargine for treating skin tumors |
AU2002350513A1 (en) * | 2001-10-09 | 2003-04-22 | Glycomed Sciences Limited | Use of solasonine for the treatment of skin tumors |
US20050130948A1 (en) * | 2002-03-27 | 2005-06-16 | Daryl Rees | Therapeutic methods and uses of sapogenins and their derivatives |
KR101130212B1 (ko) * | 2002-03-27 | 2012-04-13 | 파이토팜 피엘씨 | 사포게닌 및 그 유도체의 치료 방법 및 사용법 |
US6984725B2 (en) * | 2002-06-28 | 2006-01-10 | Solbec Pharmaceuticals Ltd. | Method for the separation of triglycoalkaloids |
AUPS329002A0 (en) * | 2002-07-01 | 2002-07-18 | Solbec Pharmaceuticals Limited | Glycoalkaloid compositions and various uses thereof |
AU2003900194A0 (en) * | 2003-01-15 | 2003-01-30 | Solbec Pharmaceuticals Limited | Methods of modulating il-6 |
TWI300352B (en) | 2003-06-05 | 2008-09-01 | G & E Herbal Biotechnology Co Ltd | Water soluble extract from plant of solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract |
CN1329038C (zh) * | 2003-06-20 | 2007-08-01 | 德英生物科技股份有限公司 | 茄属植物的水溶性萃取物、其制备方法及其药学组合物 |
GB0329667D0 (en) * | 2003-12-22 | 2004-01-28 | King S College London | Core 2 GlcNAc-T inhibitor |
US20080182801A1 (en) * | 2003-12-22 | 2008-07-31 | Btg International Limited | Core 2 glcnac-t inhibitors |
GB0513881D0 (en) * | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors III |
EP1888616A4 (de) | 2005-05-17 | 2012-05-30 | Satori Pharmaceuticals Inc | Zur behandlung von neurodegenerativen erkrankungen geeignete verbindungen |
US20070149491A1 (en) * | 2005-05-17 | 2007-06-28 | Findeis Mark A | Compounds useful for treating neurodegenerative disorders |
GB0512726D0 (en) * | 2005-06-22 | 2005-07-27 | Btg Int Ltd | Multiple sclerosis therapy and diagnosis |
GB0513883D0 (en) * | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Diagnosis of Atherosclerosis |
GB0513888D0 (en) * | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors II |
US20100056487A1 (en) * | 2006-11-20 | 2010-03-04 | Satori Pharmaceuticals, Inc. | Modulators of amyloid-beta production |
US8263755B2 (en) * | 2006-11-20 | 2012-09-11 | Satori Pharmaceuticals, Inc. | Synthesis of compounds useful as modulators of amyloid-beta production |
CN104136464A (zh) * | 2012-02-23 | 2014-11-05 | U3制药有限公司 | 用于调节放射敏感性的her3抑制剂 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR943800A (fr) * | 1946-12-31 | 1949-03-17 | Perfectionnements aux projecteurs cinématographiques utilisant des films de format réduit | |
BE722687A (de) * | 1967-10-23 | 1969-04-22 | ||
DE1900060A1 (de) * | 1969-01-02 | 1970-08-13 | Lentia Gmbh | Verfahren zur Herstellung von Androstanderivaten |
GB1380253A (en) * | 1971-01-21 | 1975-01-08 | Inverni Della Beffa Spa | Prosapogenins |
DE2519261C3 (de) * | 1975-04-30 | 1979-03-01 | Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt | Verfahren zur Gewinnung des in den Wurzeln und Rhizomen von Helleborus-Arten enthaltenen Hauptsapogenins |
NZ193564A (en) * | 1979-05-02 | 1985-01-31 | Aruba Pty Ltd | Steroid alkaloids from solanum sodomeum and pharmaceutical compositions |
US4937182A (en) * | 1985-12-19 | 1990-06-26 | Peralta Cancer Research Institute | Method for predicting chemosensitivity of anti-cancer drugs |
DK172840B1 (da) * | 1986-07-03 | 1999-08-09 | Genetic Systems Corp | Monoklonale antistoffer mod Pseudomonas aeruginosa flagella, farmaceutiske præparater indeholdende sådanne antistoffer og c |
US5227160A (en) * | 1988-07-15 | 1993-07-13 | The Biomembrane Institute | Monoclonal antibody nuh2 capable of inactivating motility of human sperm, antigen defined by said monoclonal antibody and methods of using said monoclonal antibody and antigen |
US5766632A (en) * | 1993-10-01 | 1998-06-16 | Legere Pharmaceuticals, Ltd. | Method of using lectins for contraception |
-
1991
- 1991-01-18 AU AU71594/91A patent/AU654474B2/en not_active Expired
- 1991-01-18 EP EP91901984A patent/EP0515386B1/de not_active Expired - Lifetime
- 1991-01-18 SG SG1996005588A patent/SG50585A1/en unknown
- 1991-01-18 BR BR919105952A patent/BR9105952A/pt not_active Application Discontinuation
- 1991-01-18 JP JP50258691A patent/JP3168542B2/ja not_active Expired - Fee Related
- 1991-01-18 DE DE69131861T patent/DE69131861T2/de not_active Expired - Fee Related
- 1991-01-18 WO PCT/AU1991/000020 patent/WO1991010743A1/en active IP Right Grant
- 1991-01-18 AT AT91901984T patent/ATE188036T1/de not_active IP Right Cessation
- 1991-01-18 CA CA002073855A patent/CA2073855C/en not_active Expired - Lifetime
-
1992
- 1992-07-18 KR KR1019920701699A patent/KR100213805B1/ko not_active IP Right Cessation
-
1996
- 1996-11-06 US US08/743,671 patent/US5958770A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR927003842A (ko) | 1992-12-18 |
AU7159491A (en) | 1991-08-05 |
DE69131861T2 (de) | 2000-05-18 |
EP0515386A1 (de) | 1992-12-02 |
DE69131861D1 (de) | 2000-01-27 |
JP3168542B2 (ja) | 2001-05-21 |
CA2073855C (en) | 2007-04-24 |
WO1991010743A1 (en) | 1991-07-25 |
BR9105952A (pt) | 1992-11-17 |
EP0515386B1 (de) | 1999-12-22 |
US5958770A (en) | 1999-09-28 |
JPH05503847A (ja) | 1993-06-24 |
SG50585A1 (en) | 1998-07-20 |
KR100213805B1 (en) | 1999-08-02 |
CA2073855A1 (en) | 1991-07-19 |
EP0515386A4 (en) | 1993-10-27 |
AU654474B2 (en) | 1994-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE188036T1 (de) | Glykoalkaloide | |
TR199802572T2 (xx) | V�cut a��rl���n� ayarlamada elveri�li bile�ikleri tesbit i�in tarama y�ntemleri. | |
EP0117114A3 (en) | Method and device for bacterial testing | |
DE69430365D1 (de) | Isolierung fötaler erythrozyten | |
NL300140I2 (nl) | Galanthamine, of verbindingen die eraan analoog zijn, voor behandeling van de ziekte van Alzheimer. | |
AU541099B2 (en) | Detection of occult human blood | |
NO862528D0 (no) | Metode for aa forhindre ocular hypertensjon, behandling av glaucoma og behandling av ocular hypertensjon. | |
BG101966A (en) | Application of 1l-agonist for the treatment of lack of urine retention | |
CA2224003A1 (en) | Fluorescence resonance energy transfer screening assay for the identification of hiv-1 envelope glycoprotein-medicated cell | |
NO883505L (no) | Fremgangsmaate for analyse av fluidums-innstroemning i oljebroenner. | |
Horne et al. | Detection of pregnancy specific beta1-glycoprotein in formalin-fixed tissues. | |
IT8719331A0 (it) | Mandrino per il fissaggio di cella per la centrifugazione del sangue, e simili. | |
ATE33649T1 (de) | Gegen magengeschwuer wirkende 2-guanidino-4-(2substituierte-amino-4-imidazolyl)thiazole und verfahren zu deren herstellung. | |
DE3585049D1 (de) | Monoklonale antikoerper. | |
DE69007374D1 (de) | Injektionssystem für die Behandlung von Zellen. | |
SE436751B (sv) | Forfarande enligt krav 1 i patentet 7613920-3 (publ.nr 423903) for framstellning av 17alfa-acyloxi-9alfa, 21-dihalogen-11beta-hydroxi-6alfa-fluor-16beta-metyl-pregna-1,4-dien-3,20-dion-foreningar | |
DE69624782D1 (de) | Elektrodenzuleitung für implantierbare medizinische Vorrichtung, insbesondere für Herzschrittmacher | |
KR910006478A (ko) | 인체 트립타제 유사 단백질 | |
EP0143367A3 (de) | Verfahren zur Herstellung monoklonaler Antikörper für Krebsdiagnose und Therapie | |
AU7160887A (en) | Antiparatypical antibodies, their use for detecting and treating auto-immune diseases | |
ATE40116T1 (de) | 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva. | |
EP0330924A3 (de) | Verwendung von 1,4-Dihydropyridin-Derivaten in der Behandlung von Alkoholsucht | |
RO103682B1 (ro) | Procedeu de izolare a ceruloplasminei umane | |
ES2059539T3 (es) | Metodo para la prevencion de la enfermedad del injerto frente al huesped. | |
SU1167197A1 (ru) | Штамм @ @ ИНМИ КС-7,используемый дл очистки сточных вод от 3,4-дихлоранилина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |